The Valley Desk

ArticleJournal of CancerPublished

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Fox Chase Cancer Center, Lewis Katz School of Medicine, Temple University, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Article
Venue
Journal of Cancer
Published
Subject terms
Melanoma; Toxicities; Combination Immunotherapy; Checkpoint Blockade; Vedolizumab; Tovorafenib; Plozalizumab
PubMed ID
41049010
PubMed Central ID
PMC12490977
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal